Full Print Program

FEATURE SESSIONS and diagnostics companies. She has an Finally, the financial aspects of all this will academic interest in the influence of health be debated, trying to solve the decisive economic analysis on policy and clinical issue in this context: who should bear practice, having worked at the London the financial risk related to fast-tracking School of Economics followed by doctoral clinical innovation? Industry or taxpayer? studies at the University of Oxford.  Argumentations from each perspective will be given. Plenary 1 MODERATOR 09:00 – 10:15 Adelaide Convention Centre Prof. Guy Maddern Plenary Room (Hall C) RP Jepson Professor of Surgery, University of “Fast-Tracking Clinical Adelaide, Australia Innovation: The Balance of Speed and Rigour” Professor Guy Maddern is the RP Jepson Professor While integrating clinical innovation involves of Surgery at the University risk at various stages, all stakeholders seem of Adelaide, Director of Research at the to agree with facilitating timely patient Basil Hetzel Institute for Translational Health access to clinical innovation. Research at The Queen Elizabeth Hospital and Director, Surgical Research and Plenary 1 will focus on the possible ways Evaluation (incorporating ASERNIP-S) of the of fast-tracking clinical innovation while Royal Australasian College of Surgeons. He minimizing risks related to its introduction was trained at the University of Adelaide and and management. Some crucial dilemmas became a Fellow of the Royal Australasian will have to be discussed, and possibly College of Surgeons in 1989. His clinical solved, such as: interests include the development of techniques to manage metastatic hepatic • How to minimize health risks? disease and hepatic approaches to optimize resection options. He has also published • How to deal with medico-legal risks? widely on new surgical techniques and their introduction into surgical practice. • How to include financial risks in the He has over 500 publications in scientific overall balance? journals, has contributed to over a dozen surgical texts and attracted $65 million of To have a fruitful discussion, perspectives research funding. The evaluation of new from different stakeholders such as technologies and in particular surgical policymakers, clinicians, and industry technologies is another area of focus and partners, will be included. interest. Under his supervision, ASERNIP-S has been responsible for assessing these Such a debate will be extended to existing technologies before exposing the Australian provisional registration pathways and a population to them and has provided this panoramic on them will be given. How service to the Australian and International successful have they been? What has been community for the past 20 years, and is their impact on funding decisions? The role, recognized, nationally and internationally, as current and future, of Real-World Evidence the premier surgical innovation assessment (RWE) will be integral part of the discussion. group. He is a past President of HTAi and a Is it the solution to the problem or just past Chair of INAHTA. another flawed evidence source? 51

FEATURE SESSIONS SPEAKERS through the present. He is a past Chair of the Medicare Evidence Development Dr. Clifford Goodman & Coverage Advisory Committee for the Consultant, Health Care U.S. Centers for Medicare and Medicaid Technology & Policy, Services. He is a Fellow of the American United States of America Institute for Medical and Biological Engineering. In 2022, he received the David Clifford Goodman, PhD, Banta Distinguished Career Award in Health is a Senior Vice President at Technology Assessment from HTAi. The Lewin Group, a health care policy consulting firm based in the Washington, Cliff earned a PhD from The Wharton DC, area. The Lewin Group is a unit of School of the University of Pennsylvania, Optum, a major subsidiary of UnitedHealth a Master of Science from The Georgia Group. Institute of Technology, and a Bachelor of Arts from Cornell University. Cliff has more than 30 years of experience in HTA, evidence-based health care, Ms. Olivia Nassaris comparative effectiveness research, clinical Executive Director, practice guidelines, health economics, and The Hospital Research studies pertaining to health care innovation, Foundation Group, regulation, access, and payment. He Australia directs projects for an international range of government agencies; pharmaceutical, Olivia Nassaris is the Executive biotechnology, and medical device Director of The Hospital Research companies; health care provider Foundation Group – Parkinson’s in SA, institutions; and professional, industry, and NT and the ACT and Stroke and holds patient advocacy groups. the elected position of Vice President, Parkinson’s Australia. Cliff’s recent work has involved such areas as chronic disease, infectious disease, Olivia has extensive experience in cancer, rare diseases, diagnostic testing, communications and advocacy in aged pharmacogenomics, gene therapy, care, higher education and health both in biosimilars, value frameworks, value-based Brazil and Australia. This role has enabled contracting, social determinants of health, strong expertise in business development, and applications of real-world data. Since key strategic partnerships, philanthropic 2012, he has directed a major project to grants and communications. Under Olivia’s support the development and updating of leadership, a client-centred hub focusing evidence-based clinical practice guidelines on living well as we age was created. using the rigorous GRADE methodology for the U.S. Veterans Health Administration At the heart of everything, Olivia focuses and Department of Defense. Cliff is on maximising choice, independence an internationally recognized health and wellbeing for people living with policy issues moderator and facilitator of neurological and movement disorders. With symposia, expert panels, advisory boards, that in mind, THRFG’s social enterprise, the and focus groups, having conducted Brain x Body Fitness Studio was founded hundreds of such events in recent years. which focuses on body and brain health (neuroplasticity) through exercise. A founding member of HTAi, Cliff has served on its Board, as its president, and on numerous committees for many years 52

FEATURE SESSIONS At a national level, she successfully wrote on improving quality of clinical care and a grant application to the Information, supporting uptake of innovation - as Head Linkages and Capacity Building body of of Operations at a large teaching hospital the National Disability Insurance Agency in London (UCLH), Director of Innovation, to create The Young Onset Parkinson’s Research and Life Sciences at NHS England Exchange (YOP-X) App provides information and Improvement and Chief Executive and education designed specifically for of the Accelerated Access Collaborative. people under the age of 65 living with Prior to joining NICE she invested in Parkinson’s and related conditions. It breaks early stage digital health and diagnostics down barriers connecting clients, health companies. She has an academic interest professionals, NDIA staff and contractors in the influence of health economic to access high quality education and analysis on policy and clinical practice, information. YOP-X also gives people living having worked at the London School of in regional and remote communities access Economics followed by doctoral studies at to quality information that is quick and easy the University of Oxford.  to access. Prof. Brendan Murphy AC THRFG – Parkinson’s received a $2.5m Secretary of the grant from the SA Government to fund Department of Health, 4FTE Parkinson’s Nurse Specialists and a Australia GP/Allied Health professional education campaign, ensuring increased capacity to Prior to his appointment provide improved support to people living as Secretary, Brendan was with neurological and movement disorders. the Chief Medical Officer for the Australian Government and prior to this, the Chief She is passionate about community health Executive Officer of Austin Health in and is a Director of The Maggie Beer Victoria. Foundation which aims to improve the food experience for older Australians. She Professor Murphy is: is Treasurer of the Rare Find Foundation, a childhood dementia charity for both Tay- • a Professorial Associate with the title of Sachs and Sandhoff diseases. Professor at the University of Melbourne Dr. Sam Roberts • an Adjunct Professor at Monash Chief Executive, National University and at the Australian National Institute for Health and University Care Excellence, United Kingdom • a Fellow of the Australian Academy of Health and Medical Sciences Sam Roberts is the Chief Executive of the National Institute for • a Fellow of the Royal Australian College Health and Care Excellence. She has of Physicians worked in healthcare for 20 years in a combination of clinical, operational, private • a Fellow of the Australian Institute of sector and academic roles. She originally Company Directors. trained as a doctor before undertaking an MBA and joining McKinsey and Company. He was formerly CMO and director of Her focus for the last 15 years has been Nephrology at St Vincent’s Health, and sat on the Boards of the Centenary Institute, Health Workforce Australia, the Florey Institute of Neuroscience and Mental Health, the Olivia Newton-John Cancer 53

FEATURE SESSIONS Research Institute and the Victorian South Australia from 1984 to 2007, and Comprehensive Cancer Centre. He is also a held several ministerial portfolios in former president of the Australian and New the Howard Government, including Minister Zealand Society of Nephrology. of Employment, Education, Training and Youth Affairs, Minister of Justice, and Kimberly Hill Minister for Immigration and Multicultural Managing Director of Getz Affairs. After her resignation from the Healthcare Australia and Senate in 2007, she served as the Australian New Zealand Ambassador to Italy until July 2010. She has held many positions since returning to Kimberly Hill is the Adelaide, including Chair of the Royal Flying Managing Director of Getz Doctor Service, Chair of Vision Australia Healthcare Australia and New Zealand, with and a Board member of the Port Adelaide over 20 years in the medical technology Football Club. industry. Her career started in clinical research and software engineering, Tuesday, June 27 where she developed a solid foundation in MedTech research and development. Plenary 2 Throughout her journey, Kimberly transitioned into senior sales, marketing, 08:00 – 09:15 and business development roles across the Adelaide Convention Centre United States, Japan and Asia-Pacific region. Plenary Room (Hall C) In her various international roles she “Making HTA More Efficient: successfully navigated diverse landscapes What Can we Learn about to spearhead market access initiatives Harmonization, Work Sharing and introduce new technologies. She is and Adaptation?” passionate about the MedTech’s role in partnering with healthcare providers, payers Effective integration is dependent on the and regulatory bodies to ensure sustainable sharing and harmonization of HTA across medical advancements. contexts. Plenary 2 will offer a panel discussion to explore and demonstrate Kimberly holds a Bachelor’s degree in local, regional, national, and international Mathematics and Computer Science, examples of harmonized HTA processes complemented by additional studies in and rules. The most relevant initiatives at Economics and Biomedical Engineering. regional level (America, Asia, Europe) will be Her background, global experience and presented to highlight actual experiences unwavering passion for the MedTech and practical challenges related to the industry positions her as a unique voice sharing of health technology evaluations committed to driving innovation and access (whether through adaptation or updating to life changing technology in healthcare. of existing HTA material), joint evaluations of technologies or joint submissions of Amanda Vanstone AO evidence dossiers. Amanda Vanstone is The discussion will move forward to a former Australian discuss the benefits and risks of such politician. She was a Liberal Senator for 54

FEATURE SESSIONS approaches and provide guidance on an important role of leading the global how harmonization and/or work sharing network of publicly funded HTA agencies. might be achieved at different levels. A She has participated in the work of the political perspective will be also included to European network for Health Technology highlight the benefits of harmonization in Assessment (EUnetHTA) since 2009 and Europe and Asia. represented Sweden in the EU HTA Network (HTAN) from 2013 onwards. She also acted International collaboration may be seen as as regional advisor to the WHO Egypt office the only way forward, but challenges are and the WHO in the EMRO Region. Since implicit and need to be explored a priori to 2019 she has been leading the Swedish build successful strategies. The experience Government commissioned initiative to shared in this panel will represent an establish an international collaboration on effective learning experience for the Social Technology Assessment (STA) for audience. publicly funded actors that do systematic reviews on interventions in social care. MODERATORS As a result, the International Network for Social Intervention Assessment, INSIA, was Dr. Sophie Werkö founded in 2021. She currently serves as Manager of International Secretary in INSIA. Relations & Patient Engagement, SBU, Sweden She is deputy editor in IJTAHC, member of the Editorial Board of Research Involvement Sophie has an MSc in and Engagement, and acts as reviewer and Business Administration and associate editor in several scientific journals. a PhD from the University of Stockholm. She has a longstanding engagement Prof. Brendon Kearney with HTA and started in HTA as Project Clinical Professor, Faculty Director at The Swedish Agency for Health of Medicine University of Technology Assessment and Assessment Adelaide, Australia of Social Services (SBU). She is experienced in leading, managing, and conducting Professor Kearney evidence reviews in the field of HTA. She has chaired numerous is the Director of International Relations committees including the Health Policy at SBU, responsible for coordinating SBU’s Advisory Committee on Technology international work. For many years she (HealthPACT) since 2003. For 10 years, led the work on Patient Involvement at he was the Deputy Chairman of the SBU as well as the work by the Council Medical Services Advisory Committee for Knowledge-Based Policy’s working (MSAC), Australia’s Health Technology group on patient involvement, including Assessment Committee for the assessment participants from nine government and recommendations on procedures, agencies, which resulted in a common devices and diagnostics. This involved policy for user engagement, approved in the establishment of policies and systems 2018. She is still very active in the work on for HTA assessment linked directly to Patient Involvement, both in Sweden and reimbursement decisions. He also served internationally. on the National Health and Medical Research Council for 12 years and has held As Chair of the International Network of various senior policy and management Agencies for Health Technology Assessment roles in the Australian Health System. He (INAHTA) between 2018-2020, she had is a past-Chair and current Board member 55

FEATURE SESSIONS of EuroScan International and is a current the Basque Country, University Specialist in Board member of HTAsialink. He chaired Clinical Epidemiology from the Andalusian the Population Health Research Network School of Public Health and the University for 10 years. He was Chair of the S.A. Health of Granada and Master in Bioethics from the Commission, CEO Royal Adelaide Hospital Ramon Llul University and the Borja Institute and Director Institute of Medical and of Bioethics. He has been associated Veterinary Science. professor at the School of Nursing of the Basque Health Service from 2006 to 2019 Professor Kearney has been awarded the and is external professor of Epidemiology Sydney Sax medal for services to health and Public Health at the University of the and an Order of Australia for contribution Basque Country since 2006. to emergency services and health research and the H David Banta Award He is currently the Head of Knowledge 2021 (Distinguished Career Award), Health Management and Evaluation of BIOEF, Technology Assessment International the Basque Foundation for Healthcare (HTAi). Innovation and Research. Previously, he was the coordinator of the Osteba Health SPEAKERS Technologies Life Cycle Early Warning System. He is the past-President of the Ms. Saudamini Dabak international society HTAi (2019-2021) Head of International Unit, and the President of EuroScan/iHTS, the HITAP, Thailand international network for the identification and early assessment of technologies in Saudamini Dabak is the their life cycle. Guest Director of HTA and Head of HITAP’s International Market Access at Healthclusternet. Iñaki has Unit (HIU). She started working at HITAP as collaborated in the implementation of HTA an Overseas Development Institute (ODI) initiatives in different countries including: Fellow in 2015. At HITAP, Saudamini has Argentina, Brazil, Colombia, South Korea, supported Health Technology Assessment Costa Rica, Ghana, Vietnam, Mexico, South (HTA) initiatives in Asia and Africa and has Africa, Tunisia, Norway, Israel, USA, Malaysia also been involved in conducting health and Italy (Early Warning System). He has systems research. Prior to working at also collaborated with the regional offices HITAP, Saudamini worked at the World of the World Health Organization (WHO) Bank Group. She completed her Master in the Middle East (EMRO), Asia Pacific of Arts from the Johns Hopkins School of (WPRO) and Latin America (PAHO-PAHO). Advanced International Studies (SAIS), USA, WHO Consultant Expert for the Assessment and holds a Bachelor of Arts in Economics of Emerging Health Technologies for from St. Xavier’s College, University of Low-Middle Income Countries (LMiC). Mumbai, India. Collaborator of the Inter-American Development Bank (IDB) and Imperial Dr. Iñaki Gutierrez- College London. He served as member of Ibarluzea two WHO Technical Advisory Groups to Head of Knowledge discuss on medical devices assessment Management and 2010-2012 and to support universal Evaluation, BIOEF, Spain coverage and the development of a portfolio of services since May 2019. Author Iñaki Gutierrez-Ibarluzea has of more than 80 peer-reviewed articles and a degree in Fundamental Biology and a more than 70 HTA reports, 7 monographies PhD in Neuroscience from the University of and 5 book chapters. 56

FEATURE SESSIONS Dr. Rui Santos Ivo Rui Santos Ivo graduated in Pharmaceutical President, INFARMED, Sciences by the University of Lisbon in Portugal 1987. Specialist in Hospital Pharmacy by the Ministry of Health (1992) and Rui Santos Ivo is currently the Pharmaceutical Society (2006) and President of INFARMED in Pharmaceutical Regulation by the – National Authority Portuguese Pharmaceutical Society of Medicines and Health (1997). Post graduate education on Health Products, I.P. (since June 2019) and an Law and Pharmaceutical Legislation (by invited Associate Professor of Medicines the University of Lisbon Faculty of Law Regulation, at the University of Lisbon and National School of Public Health), Faculty of Pharmacy since 2009. Pharmaceutical Medicine (by the University of Basel), Regulation (by the London School He is member of the Management Board of Economics and Political Science) and of the European Medicines Agency (EMA) on Health Management (by the Portuguese since March 2016. He is the Chair of the Catholic University, in 2000, and by AESE Heads of HTA Agencies Group (HAG), since Business School, in 2015). September 2021. He was granted with the Almofariz Along the years, at the Ministry of Health in Prize - Personality of the Year in the Portugal, he held various functions, namely: Pharmaceutical Sector (2004), recognized, Vice-president of INFARMED (2016/2019), in France, as European Correspondent President (2014/2016) and Vice-President Member of the Académie de Pharmacie (2011/2014) of the Central Administration (2014) and, for distinguished Services, of the Health System (ACSS, IP) and he he was awarded with Gold Medal of the served as President (2002-2005) and vice- Ministry of Health (2015). president (1994-2000) of INFARMED. Under his Presidency, in 2023 INFARMED In 2000-2002 he was Administrator at the was distinguished by the President of the Directorate of the EMA, in London, and in Portuguese Republic with the insignia of 2006-2008 in the European Commission, Honorary Member of the Order of the Merit. Pharmaceuticals Unit of the Directorate General for Enterprise and Industry, in Brussels. He was the first Chairman of the European Union Heads of Medicines Agencies Management Group (2004/2005) and, between the years 2008 and 2011, he was Executive Director of the Portuguese Association of the Pharmaceutical Industry (APIFARMA). Rui Santos Ivo initiated his professional career as a hospital pharmacist at Lisbon Egas Moniz Hospital (today part of CHLO- Hospital Centre Lisbon West) and in 1993 he joined INFARMED, where he initiated functions at the Licensing and Inspectorate Department. 57

FEATURE SESSIONS Ms. Suzanne McGurn Wednesday, June 28 President and CEO, CADTH, Canada Plenary 3 Ms. Suzanne McGurn 11:50 – 13:05 joined CADTH in July Adelaide Convention Centre 2020 as its President and Plenary Room (Hall C) Chief Executive Officer. She brings to the role a deep understanding of the complex “Feasibility of Aligning Technology issues surrounding the management of Evaluation Processes and pharmaceuticals, medical devices, and Decision in an Era of Sustainable clinical interventions in Canadian health systems. Development” Prior to joining CADTH, Ms. McGurn’s This Plenary builds on the discussion held distinguished career spanned clinical at HTAi 2022 on facilitating collaboration practice, patient support, and senior roles between regulators, HTA bodies and in government. Within the Ontario Ministry clinicians. In HTAi 2023 we will consider of Health, she served as the Assistant how alignment of evaluation processes and Deputy Minister of the Drugs and Devices decisions between different stakeholders Division and the Executive Officer of the might be achieved throughout the life cycle Ontario Public Drug Programs. She also led of a technology. We will explore how Early the implementation of the pan-Canadian Feasibility studies developed in partnership Pharmaceutical Alliance and served as its can be used to guide Integrated Evidence first chair. Generation that is fit-for-purpose for a range of stakeholders. We will discuss how Ms. McGurn holds both a Bachelor of parallel decision making has been used Nursing Sciences and a Master of Public to successfully drive more efficient HTA Administration from Queen’s University. and evidence-based processes across the technology lifecycle. We will have a Conference Dinner particular focus on how these alignments might be achieved in the era of technology 19:30 – 24:00 sustainability, including through the use Adelaide Oval, Ian McLachlan of in silico trials, digital twinning, and Room assessments of carbon footprint. In short, we will determine: Spend an unforgettable evening at the Adelaide Oval. Enjoy a 3-course meal and • How can we create better alignment an exclusive talk by Norman Swan. Connect between regulation, reimbursement, with fellow delegates and show us your clinical guidelines, health service moves on the dancefloor. delivery and re-assessment of health technologies? • Is living HTA possible when health systems are siloed and often duplicative? • How can we work to achieve better alignment, given health system, environmental and resourcing constraints? 58

FEATURE SESSIONS The aim is to develop a roadmap for SPEAKERS integrated evidence generation and efficient decision-making that can inform decisions Jessica Bean made by clinicians in consultation with Chairperson, Patient Voice patients, right through to public funding Initiative, Australia decisions made by a payer. Jessica Bean is a MODERATOR medicines access advocate, international speaker, Dr. Norman Swan consultant, and empowerment coach for Host, Radio National’s young women living with chronic illness. Health Report, Australia Informed at age 21 that she would need Dr Norman Swan AM a double lung transplant to survive the MBChB, FRCP, DCH, MD damage caused to her lungs by the genetic (Hon Causa), FAHMS. condition cystic fibrosis, Jessica fought hard to change her trajectory. Well over a Norman co-hosts RN’s Health Report decade later, Jessica continues to breathe and during the COVID-19 pandemic, has through her own lungs and live a life co-hosted Coronacast, a podcast on the beyond her diagnosis. coronavirus. Norman is also a reporter and commentator on the ABC’s 7.30, Jessica’s experience as one of the first Midday, News Breakfast and Four Corners Australian cystic fibrosis patients with her and a guest host on RN Breakfast. He is a gene mutation to benefit from genetic past winner of the Gold Walkley and has modulation therapy, gave her an intimate won other Walkleys including one with understanding of the importance of clinical his Coronacast colleagues in 2020. He trials and the emerging challenges faced created Invisible Enemies, on pandemics by patients in the age of personalised and civilisation for Channel 4 UK and SBS medicine. This has inspired a mission which was subsequently broadcast in 27 to ensure patients and their values are countries. Norman has been awarded represented in decision making across the the medal of the Australian Academy health ecosystem. of Science, an honorary MD from the University of Sydney and in October 2022 Jessica has been involved in advocacy a Fellowship of the Australian Academy of work across the world including speaking Health and Medical Sciences. On Australia engagements in the USA, Europe, and Day 2023, Norman was awarded the Medal the Asian Pacific Region. Her work has of the Order of Australia (AM). been recognised by global healthcare organisations and brands including Bupa During COVID he wrote two books. So for whom she was a finalist in their health You Think You Know What’s Good For You influencer awards. (Hachette) is a best seller and was released in the UK. His latest book So You Want To Jessica is currently chairperson for Patient Live Younger Longer has also been on the Voice Initiative (Australia), host of the best seller list. Patient Voice Podcast and is a consumer representative of The Australian Genomics Norman trained in medicine and paediatrics Community Advisory Group. She has in Aberdeen, London and Sydney before previously held consumer advisory and joining the ABC. chair roles for state and local hospital 59

FEATURE SESSIONS district healthcare organisations. Jessica Dr. Cristina Curreli is proud to be an ambassador for the Researcher, University of international Hello My Name Is campaign. Bologna, Italy Undoubtedly though, the role Jessica Cristina Curreli is a is most proud of is being mum to her research fellow at University daughter Aurelia who was born in 2022 – a of Bologna and at the Rizzoli privilege that has been made possible by Orthopedic Institute (Italy). She received a the incredible advancements in treatments PhD in Biomechanics at the University of that have occurred for patients with cystic Pisa (Italy). Her research activities mainly fibrosis in Jessica’s lifetime. focus on the development and validation of patient-specific models to support clinical Dr. Meindert Boysen decisions (Digital Twins in Healthcare) and Head of International Affairs, of computer modelling & simulations that NICE, United Kingdom can be used to complement real world clinical trials and generate additional Meindert is responsible information to assess the safety and/or at NICE for international the effectiveness of new medical product partnership working, developing (In Silico Trials). She is currently working NICE’s role in international fora and on the definition of specific techniques representing NICE at key international to assess the credibility of computational meetings, further sustaining and developing models and on the regulatory activities NICE’s international reputation. Until needed for the qualification of these novel recently, Meindert was the director at NICE digital methodologies to be used in clinical responsible for delivery of the programmes practice. that together form the centre for health technology evaluation. Including the Dr. Daphne Khoo technology appraisals, highly specialised Deputy Director of Medical technologies, medical technologies Services, Ministry of Health evaluation, diagnostic assessment and Singapore, Singapore interventional procedures programmes. After qualifying as a pharmacist from Dr. Daphne Khoo is Utrecht University, he worked in a currently the Deputy Director hospital in the Netherlands, and held of Medical Services (DDMS) (Healthcare positions in health outcomes and sales Performance Group - HPG) as well as the in the pharmaceutical industry. Meindert founding Executive Director of the Agency completed the MSc in Health Policy for Care Effectiveness (ACE). Planning and Financing at the London School of Hygiene and Tropical Medicine As DDMS (HPG) she leads the Ministry and the London School of Economics of Health’s teams which oversee Patient & Political Sciences and briefly worked Safety, Clinical Outcomes, Value Driven for the King’s Fund before starting at Care, Population Health Indicators, NICE in 2004. Meindert was a member Healthcare System Indicators and the of the Board of NICE and a director of National Improvement Unit. ACE is the board of the International Society Singapore’s national Healthcare Technology for Pharmacoeconomics and Outcomes Agency which conducts clinical and cost Research (2017-2020). effective evaluation of drugs and device classes prior to coverage decisions by the Ministry of Health (MOH). ACE also issues 60

FEATURE SESSIONS MOH’s Appropriate Care Guides which large databases, economic methodologies, guide clinical practice nationally. and decision analysis. Dr. Khoo received her Endocrinology Andrea Rappagliosi training at the Singapore General Hospital Senior Vice-President, and the Cleveland Clinic, USA. She spent Public Affairs EMEA- earlier years of her career in clinical and Canada-LatAm, Edwards translational research, as well as in the Lifesciences , Switzerland private sector. As Chief Medical Officer, Fortis Healthcare, she had responsibilities Andrea is currently Senior in 11 countries including India and Vietnam. Vice-President Public Affairs EMEA, Canada She is a Past President of the Endocrine and LATAM at Edwards Lifesciences and Metabolic Society, Singapore, ASEAN and member of the regional Executive Federation of Endocrine Societies as well Leadership Team. He is leading the as the Association of Women Doctors, Government Affairs, Market Access, Singapore. Communication and Patients Advocacy engagement for the company. Dr. Nicole Mittmann Chief Scientist and Vice Born in Rome, Andrea received a law President, Evidence degree from the University of Rome, La Standards, CADTH, Canada Sapienza. Andrea began his professional career in the Italian Senate. Recently he In her Chief Scientist role, worked in the Sanofi group as VP Public Dr. Mittmann is responsible Affairs Europe and at SPMSD Joint Venture for ensuring that CADTH actively learns, where he was member of its Executive ensures rigour and quality, mobilizes Committee from 2012 to 2016. Before, evidence, and links science to strategy. In he worked at Baxter Healthcare, Serono her Evidence Standards role, Dr. Mittmann International and GSK in different European leads CADTH’s shared science groups, and International positions in the public including the Health Economics, Research affairs and market access policy area. Information Services, Scientific Affairs, Publishing, Early Scientific Advice and Real- Andrea is the Chair of the MedTech Europe World Evidence teams. HTA Committee and he is member of the Board of the European Patient Safety In her academic capacity, Dr. Mittmann Foundation (EUPSF). holds an MSc and PhD in pharmacology from the University of Toronto. She holds a In the last ten years, Andrea represented the faculty position as an assistant professor at healthcare Industry in several European EU the University of Toronto in the Department Commission and Member States initiatives of Pharmacology & Toxicology; and is such as the HTANetwork, EUnetHTA Joint- cross-appointed to the Institute for Health Action 3, and the EU Active & Healthy Aging Policy, Management and Evaluation. She Innovation Partnership and the EU Joint is also an associate scientist at Sunnybrook Action on Vaccination. He was President Health Sciences Centre in Toronto, of EuropaBio the European Association Canada. Dr. Mittmann has conducted and of the biotech Industry (2009-2011), collaborated on notable research in the and of Vaccines Europe, the European areas of economic evaluations, outcomes Vaccines manufacturers association research, and drug/patient safety. Research (2013-2017). Andrea is a founding member methodologies include the examination of of the Global Policy Forum at HTAi – the 61

FEATURE SESSIONS scientific and professional society for Closing Ceremony and all those who produce or use health Presentation of Awards technology assessment (HTA) and he is currently chairing the MedTech Europe HTA 13:05 – 14:00 Committee. Adelaide Convention Centre Plenary Room (Hall C) Prof. Andrew Wilson Chair, PBAC, Australia Official handover from Outgoing HTAi President, Dr. Wija Oortwijn, to Professor Wilson is Co- Incoming HTAi President, Dr. Rabia Director of the Menzies Sucu Centre for Health Policy and Economics and International Journal Of Technology Professor of Public Health Assessment In Health Care (IJTAHC) in the School of Public Health, the Awards University of Sydney. He co-leads the NHMRC Australian Prevention Partnership EGON JONSSON AWARD Centre (Sax Institute). He is the Chair of Award Presenter: Dr. Rabia Sucu the Pharmaceutical Benefits Advisory Committee for the Australian Government. Jill Sanders Memorial Award He has specialist qualifications in public health and clinical medicine, and a PhD in Award Presenter: Dr. Rabia Sucu epidemiology. HTAi Educational Scholarship Award His research interests concern how evidence can better inform decision Award Presenter: Dr. Rabia Sucu making in clinical medicine, public health, and health service policy and planning. Sigrid Droste Award His publications include aspects of prevention and management of chronic Award Presenter: Dr. Wija Oortwijn disease, evaluation of the effectiveness and responsiveness of health care systems HTAi Annual Meeting and the impact of social and physical Presentation Awards environment on health. • B est Oral Presentation • Best Student Oral Presentation • Best Poster Presentation • Best Student Poster Presentation Award Presenters: Prof. Wim Goettsch, the Netherlands and Prof. Guy Maddern, Australia Introduction to HTAi 2024 Annual Meeting in Seville, Spain, June 15-19, 2024 • Dr. Juan Antonio Blasco-Amaro Closing Remarks • Dr. Rabia Sucu, HTAi President, Ukraine 62

FEATURE SESSIONS Collaborative Engagement Sessions Sunday, June 25 Tuesday, June 27 Early Career Meet & Greet * ‘Changing Conversations’ Hosted by the Australian 18:15 - 19:00 HTA Consumer Gilbert Suite Consultative Committee Exclusive networking session specifically 11:10 - 12:25 for early career professionals. This session Gilbert Suite will provide a unique opportunity to forge connections, share experiences, and Consumer focused presentation and a build a support network within the HTA panel discussion, followed by a brunch & community. mingle. *By invitation only. This session is primarily targeted at consumers; however, it is open to all Monday, June 26 meeting attendees. ‘International Wednesday, June 28 Collaboration Roundtable’ hosted by the Australian Is HTA Ready for GPT/AI Government, Department Large Language Models? of Health and Aged Care * A Participative “Fishbowl” Session 12:05 - 13:05 Gilbert Suite 9:10 - 10:25 Gilbert Suite This roundtable provides a platform for government officials from around the world In this participative session, we will: 1) to share insights and knowledge on HTA identify applications of GPT/AI and 2) policy, methods, and regulation; as well propose how HTA may need to adapt to as build new relationships and learn from assess the effectiveness and safety and peers. economic, social, ethical, and other impacts of GPT/AI-based technology as well as how *By invitation only. GPT/AI may alter HTA methodology itself. 63

64

Workshops

WORKSHOPS Workshops WS05 Patient and Citizen Involvement in Health Technology Assessment Saturday, June 24, 2023 08:30 – 16:30 WS01 Research Oriented Market Access University of Adelaide, 1059B for Adopting High-Cost Therapies – Principles and Practice Ann Single, Australia Anke Peggy Holtorf, Switzerland 08:30 – 12:00 Eunice Low, France University of Adelaide, 1059A David Chandler, UK Sally Wortley, Australia Jeff Round, Canada Janney Wale, Australia Erin Kirwin, Canada Barry Liden, USA Sasha van Katwyk, UK Ana Toledo Chavarri, Spain Heidi Livingstone, UK WS02 Introduction to Ethics in Health Kate Morgan, UK Technology Assessment Todd Stephenson, Australia 08:30– 12:00 WS06 Patient-Reported Outcomes for University of Adelaide, 5052A Health Technology Assessment Pietro Refolo, Rome 08:30 – 16:30 Bart Bloemen, Netherlands University of Adelaide, 6052 A/B Ken Bond, Canada Drew Allen Carter, Australia Richard De Abreu Lourenco, Australia Björn Hofmann, Norway Brendan Mulhern, Australia Sharon Kessels, Australia Rosalie Viney, Australia Dario Sacchini, Italy Constanza Vargas, Australia Lars Sandman, Sweden Rebecca Addo, Australia Michal Stanak, Austria Gert Jan van der Wilt, Netherlands WS07 Introduction to GRADE for Establishing the Certainty of Evidence WS03 HTA 101: Introduction to Health in Systematic Reviews and Health Technology Assessment Technology Assessment 08:30 – 12:00 08:30 – 16:30 University of Adelaide, 4050 A/B University of Adelaide, 5052B Clifford Goodman, USA Zachary Munn, Australia Timothy Barker, Australia WS04 Automation Tools to Improve the Speed of Conducting Systematic Reviews 08:30 – 12:00 University of Adelaide, 1068 Justin Clark, Australia 66

WS08 An Introduction to Early Health WORKSHOPS Technology Assessment Sunday, June 25, 2023 08:30 – 16:30 University of Adelaide, 3066 WS12 A Workshop to Learn About “Why” and “How” to Assess the Impacts of Janet Bouttell, UK Health Technology Assessment Andrew Partington, Australia 08:30 – 12:00 WS10 The Road to Policy and Clinical University of Adelaide, 4050 A/B Integration in Genomic Medicine, Advanced Diagnostics & Advanced Charlotte Pelekanou, UK Therapeutic Products Sylvie Bouchard, Canada Grace Li-Ying Huang, Taiwan 13:00 – 16:30 Erni Zurina Romli, Malaysia University of Adelaide, 4050 A/B WS13 HTA of Artificial Intelligence: Richard Charter, UK Experiences and Challenges WS11 HTAi Interest Group on Rare 08:30 – 12:00 Diseases – Developing a Workplan University of Adelaide, 3066 13:00 – 16:30 Rossella Di Bidino, Italy University of Adelaide, 1068 Dario Sacchini, Italy Americo Cicchetti, Italy Karen Facey, UK Murilo Contó, Italy Steve Pearson, USA Jim Thomson, USA WS14 Engaging Stakeholders to Fleur Chandler, UK Strengthen Health systems in Low- Nicole Millis, Australia and Middle-Income Countries (LMICs) Sheela Upadhyaya, UK moving towards Universal Health Eric Low, UK Coverage Alicia Granados, Spain Vinciane Pirard, Belgium 08:30 – 12:00 Alfonso Iorio, Canada University of Adelaide, 6052 B Monica Ferrie, Australia Clare Stuart, Australia Jani Mueller, South Africa Jessica Bean, Australia Anke Peggy Holtorf, Switzerland Francois Houyez, France Lauren Pretorius, South Africa Marilia Mastrocolla de Almeida Cardoso, Brazil NurFana Binti Mohamad, Malaysia 67

WORKSHOPS WS15 Values in Doing Assessments of WS18 Indigenous Populations and Healthcare Technologies (VALIDATE) Health Technology Assessment – International Collaboration to Improve 08:30 – 12:00 Knowledge, Health Policy and Equity University of Adelaide, 6052 A 08:30 – 16:30 Bart Bloemen, Netherlands University of Adelaide, 1059 A Carla Fernández Barceló, Spain Pietro Refolo, Italy Jane Thomas, New Zealand Iñaki Gutiérrez Ibarluzea, Spain Trevor Simpson, Australia Wija Oortwijn, Netherlands Dawn Casey, Australia Gail Garvey, Australia WS16 Advanced Workshop in Kristen Howard, Australia Information Retrieval: New Challenges Nicole Mittman, Canada and Updated Approaches in Efficient HTA Literature Searching WS19 The Newcomer’s Guide to HTA: Handbook for HTAi Early Career 08:30 – 16:30 Network University of Adelaide, 7052 A/B 13:00 – 16:30 Amanda Hodgson, Canada University of Adelaide, 4050 A/B Catherine Voutier, Australia Siw Waffenschmidt, Germany Maoling Wei, China Justin Clark, Australia Alric Ruether, Germany Guido Zuccon, Australia Ken Bond, Canada Jane Wale, Australia WS17 HTA 102 Hospital-Based HTA in the David Hailey, Australia Life Cycle Approach Current Scenarios Iñaki Gutierrez Ibarluzea, Spain Americo Cicchetti, Italy 08:30 – 16:30 University of Adelaide, 5052 A/B WS20 All Things Publishing: Submitting to HTAi’s Journal (IJTAHC) - What’s your Americo Cicchetti, Italy Article Type and Hot Topics in Publishing Marco Marchetti, Italy Rossella Di Bidino, Italy 13:00 – 16:30 Iga Lipska, Poland University of Adelaide, 6052 B Laura Sampietro Colom, Spain Guy Maddern, Australia Wendy Babidge, Australia Andrey Avdeyev, Kazakhstan Wim Goettsch, Netherlands Rabia Sucu, Ukraine Sophie Werkö, Sweden Ann Single, Australia Tara Schuller, Canada 68

WORKSHOPS WS21 Horizon Scanning for Technology Forecasting 13:00 – 16:30 University of Adelaide, 3066 Iñaki Gutierrez Ibarluzea, Spain Hans Peter Dauben, Germany Maxmillian Otte, Germany WS22 The Design of Health Technology Assessment Processes Using Evidence- Informed Deliberative Processes in Low and Middle Income Countries 13:00 – 16:30 University of Adelaide, 6052 A Wija Oortwijn, Netherlands Maarten Jansen, Netherlands Maryam Huda, Pakistan Lyazzat Kosherbayeva, Kazakhstan 69

Patients are our life’s work … At Edwards Lifesciences we are driven by a passion for patients and dedicated to improving lives. It’s about uncovering bold advancements, innovating structural heart and critical care technologies–and dreaming big to imagine brighter futures. It all adds up to embracing the urgency to make a difference where it matters most. It’s our mission for life … … and life is now. Edwards, Edwards Lifesciences, the stylized E logo, and Life is Now are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. © 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-1611 v4.0 Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com 70

Panels

PANELS Panels PN04 HTA in Medical Devices Panel Session 1 Riverbank 5, lower level Monday, June 26, 2023, 13:15 – 14:30 Murilo Contó, Brazil Rossella Di Bidino, Italy PN01 Best Practice Considerations on Elizabeth Flynn, Australia the Assessment of Robotic-Assisted Paul Dale, Australia Surgical Systems Aline Silveira Silva, Canada Riverbank 3, lower level PN06 Outcomes and Lessons from Implementing the International Jamie Erskine, UK Summary of Information for Patient Richard Charter, UK Groups in Different HTA Systems Ben Forrest, USA Guy Maddern, Australia Plenary Room (Hall C), ground level PN02 Coverage with Evidence Sally Wortley, Australia Development: Can we Align Haley Andersen, Australia Perspectives? Valentina Strammiello, Belgium Mark Brooke, Australia E3, ground level Eric Low, UK Haitham Tuffaha, Australia PN07 Rare Disorders. Is the Lack of Dalia Dawoud, UK Effect in a Patient-Reported Outcome, Julia Lewis, Australia Reflecting no Benefit? Ann Single, Australia Colman Taylor, Australia Riverbank 7, lower level PN03 HTA & Traditional, Complementary Alicia Granados, Spain & Integrative Healthcare (TCIH) in Asian- Neil Bertelsen, Germany Pacific region Alfonso Iorio, Canada Elena Nicod, Italy Riverbank 6 , lower level PN08 The Value and Impact of Health Maoling Wei, China Technology Assessment: 2023 HTAi Jian Ping Liu, China Global Policy Forum Summary Myeong Soo Lee, Korea Jennifer Hunter, Australia Riverbank 4, lower level Americo Cicchetti, Italy Daniel Ollendorf, USA Rebecca Trowman, Australia Tracy Merlin, Australia Kyle Hvidsten, USA Stella O’Brien, UK David Hailey, Australia 72

PANELS PN09 What is Early HTA and How Can PN12 Do We Need Innovative it Facilitate Timely Patient Access to Evidentiary Approaches to Assess Digital Valuable Innovation? Technologies? Riverbank 8, lower level Riverbank 5, lower level Janet Bouttell, UK Laura Sampietro Colom, Spain Andrew Partington, Australia Joice Valentim, Switzerland Carla Fernandez, Spain Rosa Hildalgo Vivianco, Spain Alicia Norman, Australia Magdalena Ruth Moshi, Australia Jonathan Karnon, Australia Marco Marchetti, Italy PN10 ZEN and the Art of Health PN13 From Global to Local: what value Technology Assessment from policy fora in HTA for patients, industries and assessors? E1, ground level Riverbank 4, lower level Alric Rüther, Germany Wim Goettsch, Netherlands Americo Cicchetti, Italy Laura Sampietro Colom, Spain Alicia Granados, Spain Keng Ho Pwee, Singapore Andrea Rappagliosi, Switzerland Steve Pearson, USA Dan Ollendorf, USA Manuel Antonio Espinoza, Argentina Panel Session 2 Francesco S. Mennini, Italy Monday, June 26, Ann Single, Australia 17:25 – 18:40 Guy Maddern, Australia PN11 Balancing Speed and Rigour in PN14 HTA Driving Use of Registries to Patient Preference Studies: The Key to Optimize Treatment for Paediatric Spinal Better Integration into HTA Decision Muscular Atrophy Making? Riverbank 7, lower level Gilbert Suite, ground level Nicole Mittmann, Canada Evi Germeni, UK Karen Facey, UK Barry Liden, USA Wim Goettsch, Netherlands Simon Fifer, Australia Sylvie Bouchard, Canada Deborah Marshall, Canada Ashley Jaksa, USA Julie Cini, Australia 73

PANELS PN15 Health Technology Assessment PN18 No Time to Waste – Healthcare as Reforms: Drivers, Processes, and an Investment in the Future Motivations Leading to Change. The Case of Australia, England, and E3, ground level Netherlands Edward Cavanough, Australia Riverbank 8, lower level Morris Iemma, Australia Penny George, Australia Martina Garau, UK Michelle Burke, Australia Jonathan Karnon, Australia Mark Neeham, Australia Meindert Boysen, UK Wija Oortwijn, Netherlands PN19 Towards a Joint Capacity Building Suzanne McGurn, Canada through the Family of Health Technology Assessment PN16 How Can We Improve HTA of Genomics? Aligning the Academic, E1, ground level Patient and Industry Perspectives. Rosmin Esmail, Canada Riverbank 3, lower level Nora Ibargoyen Roteta, Spain Maximilian Otte, Germany Colman Taylor, Australia Alric Ruether, Germany Andrea Kunca, Australia Izzuna Mudla Mohamed Ghazali, Malaysia Tiffany Boughtwood, Australia Hans Peter Dauben, Germany Krystal Barter, Australia Panel Session 3 PN05 ICER Thresholds in Tuesday, June 27, Reimbursement Frameworks: 11:10am – 12:25pm Challenges and Experiences in the Asia Pacific PN20 Can Regulators and Health Technology Assessment Agencies Sing Riverbank 6, lower level from the Same Hymn Sheet? Exploring The Benefits and Challenges Jeonghoon Ahn, South Korea Jonathan Tan, Singapore E3, ground level Tracy Merlin, Australia Rosalie Viney, Australia Tracy Merlin, Australia Suzanne McGurn, UK PN17 Moving Towards Harmonizing Jae Kyung Suh, Korea Patient Involvement in Health Meindert Boysen, UK Technology Assessment (HTA) through Wim Goettsch, Netherlands Stakeholder Recommended and Valued Processes Plenary Room (Hall C), ground level Anke Peggy Holtorf, Switzerland Valentina Strammiello, Belgium Aline Silveira Silva, Canada Eunice Low, France 74

PANELS PN21 Can the U.S. Adopt a More PN25 Hospital-Based HTA for Health Comprehensive, Coordinated Approach Service Delivery Models: Comparing, to HTA? Contrasting and Learning from Experience Riverbank 8, lower level Riverbank 7, lower level Barry Liden, USA Jonathan Karnon, Australia Dan Ollendorf, USA James Le Fevre, New Zealand William Padula, USA Penny Reeves, Australia Christoph Glaetzer, USA Pwee Keng Ho, Singapore Andrew Partington, Australia PN22 Capacity Building in Health Technology Assessment across Eastern PN26 How Can We Better Manage Europe and Central Asia Uncertainty in HTA? Aligning the Academic, Patient and Industry Perspectives. E1, ground level Plenary Room (Hall C), ground level Birol Tibet, Turkey Lyazzat Kosherbayeva, Kazakhstan Colman Taylor, Australia Nabil Seyidov, Azerbaijan Bonny Parkinson, Australia Rabia Sucu, Ukraine Rachael Anderson, Australia Wija Oortwijn, Netherlands Clare Stuart, Australia PN23 Growing Green: Raising PN28 Legal Structure for Establishing an the Importance of Environmental HTA Organization: Low- and Middle- Considerations in Health Technology Income Countries’ Perspective Assessment to Support Sustainable Health Systems Riverbank 6, lower level Riverbank 5, lower level Jani Mueller, South Africa Yingyao Chen, China Nicole Mittmann, Canada Paul Fennessy, Australia Gavin Outteridge, UK Tara Schuller, Canada PN24 Hospital-Based HTA: An Additional Value at Local Level or is it just a Duplication of Work? Riverbank 4, lower level Americo Cicchetti, Italy Marco Marchetti, Italy Rossella Di Bidino, Italy Iga Lipska, Switzerland Laura Sampietro Colom, Spain Guy Maddern, Australia Andrey Avdeyev, Kazakhstan 75

PANELS Panel Session 4 PN33 HTA Capacity Building in Asia: Tuesday, June 27, HTAi Asia Policy Forum 2022 Findings 14:55 – 16:10 Riverbank 4, lower level PN30 Equity in Health Technology Assessment: Approaches to Incorporate Guy Maddern, Australia Equity Concerns into Healthcare Linda Mundy, Australia Decision Making Grace Huang, Taiwan Izzuna Ghazali, Malaysia Gilbert Suite, ground level Vanessa Xavier, Australia Alex Best, Singapore Manuel Espinoza, Chile Pietro Refolo, Italy PN34 Policy Implications of Ramiro Gilardino, USA Reimbursement and Clinical Integration Jane Thomas, New Zealand of Complex Innovations, Examples from Camille Schubert, Australia Cell Therapy and Gene Editing Ann Single, Australia Riverbank 8, lower level PN31 Evidence - Interaction - Trust - Confidence Meindert Boysen, UK Tiffany Boughtwood, Australia E3, ground level Paul Fennessey, Australia Klair Bayley, Australia Wija Oortwijn, Netherlands Katrina Lapham, Australia Iñaki Gutierrez Ibarluzea, Spain Franz Pichler, Australia Inka Heikkinen, Switzerland Hans Peter Dauben, Germany PN35 Real World Evidence from Rare Disorders’ Registries. A Problem or Part PN32 How to Balance Benefits and Risks of the Solution to Inform Decisions on Cellular and Gene Therapies: HTA Perspective from Selected Countries? E1, ground level Riverbank 3, lower level Karen Facey, UK Michel Tchan, Australia Yingyao Chen, China Conan Donnelly, Ireland Lizheng Shi, USA Pall Jonsson, UK Jeonghoon Ahn, South Korea Sheela Upadhyaya, UK Ruoyan Gai, Japan PN36 The Highway to Evidence? Re- using and Sharing Existing Evidence Riverbank 7, lower level Siw Waffenschimidt, Germany Justin Clark, Australia Zachary Munn, Australia Tara Schuller, Canada Klas Moberg, Sweden 76

PANELS PN37 Uncertainty Regarding the Long- PN40 Evaluating New Genetic and term Effectiveness of New Therapies in Genomic Tests in Health Technology Health Technology Assessment Assessment: How to Define and Measure Value? Riverbank 5, lower level Riverbank 3, lower level Jan Willem Versteeg Wim Goettsch, Netherlands Sarah Norris, Australia Nicole Mittmann, Canada Nicole Millis, Australia Hong Ju, Singapore Gillian Mason, Australia Andrew Bruce, Australia Jack Nunn, Australia Deborah Marshall, Canada PN38 What Managerial Skills for Patient Simon Fifer, Australia Associations Active in HTA? Discussions and Practical Examples PN41 Exploring the Implications of Accelerated Access Pathways for Plenary Room (Hall C), ground level Promising New Medicines on HTA and Patient Access Americo Cicchetti, Italy Valentina Strammiello, Belgium Riverbank 7, lower level Eugenio Di Brino, Italy Rabia Sucu, Ukraine Daniel Ollendorf, USA Emma Andrews, USA Meindert Boysen, UK Maria Teresa Petrangolini, Italy Nicole Mittmann, Canada Richard Vines, Australia Andrew Wilson, Australia Ann Single, Australia Panel Session 5 Gavin Lewis, Switzerland Wednesday, June 28, 09:10 – 10:25 PN42 How Can We Make Better Use of RWE for HTA? Aligning the Academic, PN39 Estimation of lifetime survival Patient and Industry Perspectives. function for health technology assessment (HTA): Methods and E1, ground level empirical examples Colman Taylor, Australia Riverbank 6, lower level Lucas Tocchini, Australia Sallie Pearson, Australia Jung der Wang, Taiwan Jessica Bean, Australia Paul Dickman, Sweden Jing-Shiang Hwang, Taiwan Mathuros Tipayamongkholgul, Thailand 77

PANELS PN43 Managed Entry Agreements for High-Cost, One-Shot Curative Therapies? - A Calculation Tool to Determine their Desirability E3, ground level Marcelien Callenbach, Netherlands Wim Goettsch, Netherlands Camille Schubert, Australia PN44 Patients as Active Contributors to Horizon Scanning Plenary Room (Hall C), ground level Uwe Siebert, Austria François Houÿez, France Rob Camp, Spain PN45 RWE: Experiences & Challenges for Decision Making in Latin America - 2022 Latin America Policy Forum Findings Riverbank 4, lower level Manuel Espinoza, Chile Andres Pichon-Riviere, Argentina Joice Valentim, Switzerland PN46 Using Quantitative Patient Preference Data to Assist HTA Decision-Making Riverbank 5, lower level Yingyao Chen, China Lizheng Shi, USA Lei Si, Australia Yan Wei, China Shimeng Liu, China 78

Radboud university medical centre Free download (CC BY-NC-ND 4.0) at — Department for Health Evidence www.radbouduniversitypress.nl and www.validatehta.eu Radboud university medical centre (Radboudumc), located ISBN 9789083178950 in Nijmegen, is one of the eight university hospitals in the DOI https://doi.org/10.54195/CKHB1659 Netherlands. It specializes in patient care, scientific research, teaching and training in order to have a significant impact on In the 2018-2021 EU Erasmus+ strategic partnerships project healthcare. “VALues In Doing Assessments of healthcare TEchnologies” (VALIDATE), a consortium of seven academic and HTA organ- The HTA group, part of the Department for Health Evidence, izations have developed an approach to HTA that allows for is internationally recognized for its excellent reputation in the integration of empirical analysis and normative inquiry. research and education in health sciences. The group has broad in-house knowledge and expertise about all aspects The VALIDATE handbook offers the reader an opportunity to related to HTA. get acquainted with the theoretical considerations and ap- prehend the associated practical and organizational implica- The activities are centered around the development of HTA tions of this approach. It offers those interested in HTA to reports, methodologies to improve decision-making pro- integrate empirical analysis and normative inquiry in a trans- cesses as well as improving the institutional HTA capacity in parent way. countries around the globe. Examples include the VALIDATE approach (see The VALIDATE handbook) and Evidence-Informed The handbook is endorsed by HTAi and EuroScan-iHTS. Deliberative Processes (EDP) for HTA. The EDP guide can be downloaded via: https://www.radboudumc.nl/en/research/ research-groups/global-health-priorities/our-products/prac- tical-guide/practical-guide. The research program of the HTA group serves as basis for academic teaching, training of Master and PhD students and those interested in HTA and global health. 79

Under the microscope,© Vincent Fournier R&D plateform, Vitry-sur-Seine, France We’re an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. 80

Orals

ORALS Oral Presentations OP06 Development of a Tool to Support the Collection of Policy-Relevant, Oral Session 1 Stakeholder-Informed Clinical Evidence Monday 26 June, for Innovative Digital Health Technologies 14:40 – 15:40 Presenter: Amy Von Huben OS01 Innovative Insights in Disease Management OP07 Eleven Years of CONITEC: Advances and Challenges of Patient and Riverbank 8, lower level Public Involvement in Brazilian Health Technology Assessment Process OP01 Causal Association between Type 2 Diabetes Mellitus and Risk of Cancer Presenter: Clarice Moreira Portugal Presenter: Fabiola Lemus OP08 International Benchmark of Health Technology Assessment Training OP52 Treating Osteoporosis in Tools and Materials for Patients and Postmenopausal Women with Consumers Denosumab (Prolia®): A Systematic Review and Network Meta-Analysis Presenter: Eunice Low Presenter: Magdalena Ruth Moshi OP09 Developing a Patient and Consumer Training Tool Explaining Health Technology OP04 The Efficacy of Segmentectomy Assessment and Patient/Consumer and Lobectomy for Non-Small Cell Lung Participation: The French Experience Cancer 1-2 cm: A Systematic Review and Meta-Analysis Presenter: Eunice Low Presenter: Kai Zhao OS03 Global Perspectives on Cost-Effective Cancer OP159 Quality of Evidence and Clinical Therapies Benefit of Cancer Medicines Assessed for Funding in Australia Riverbank 6, lower level Presenter: Agnes Vitry OP11 Cost-Effectiveness of Atezolizumab plus Chemotherapy as OS02 Patient Involvement First-Line Treatment for Metastatic Non- in HTA: Tools & Squamous Non-Small Cell Lung Cancer. Challenges Presenter: Liu Liu Plenary Room (Hall C), ground level OP12 Cost-Effectiveness Comparison of PD-(L)1 Inhibitors in First-Line Treatment 82 of Advanced Non-Squamous Non-Small Cell Lung Cancer in China Presenter: Yi Yang

ORALS OP13 Cost-Effectiveness Analysis of OS05 Patient Values, Sintilimab plus Chemotherapy for the Gender Medicine in HTA: First-Line Treatment of Non-Squamous Insights from Cancer, Non-Small-Cell Lung Cancer: Societal Mental Health & Surveys Perspective Riverbank 3, lower level Presenter: Fuming Li OP21 Patient Values Project (PVP): OP14 Cost-Utility Analysis of Patient preferences for Cancer Regorafenib for Patients with Treatments to Inform a Framework Hepatocellular Carcinoma who Incorporating Patient Values into HTA Progressed on Sorafenib Treatment Presenter: Deborah A Marshall Presenter: Ambrish Singh OP22 Benchmarking of Population- OS04 Building Global Based Childhood Cancer Survival by Capacity for HTA Toronto Stage: Know the Differences to Propose Effective Interventions E1, ground level Presenter: Rosalia Ragusa OP10 Standardised Multi-Lingual Reporting of Health Technology OP45 HTA and Gender Medicine: Time Assessment and Stakeholder to Take Action! Involvement Presenter: Rosalia Ragusa Presenter: Jack Nunn OP24 Depressed and Depression-Prone OP18 Laying the Foundation for Groups’ Preference with regard to Sustainable Health Technology Antidepressants in China: A Best-Worst Assessment Training Program in Ukraine Scaling Survey Presenter: Rabia Sucu Presenter: Shimeng Liu OS07 Healthcare Models: Economic Evaluation Riverbank 4 OP31 Societal Opportunity Costs: Incorporating Impacts that Fall Outside the Healthcare Sector Presenter: Laura Edney 83

ORALS OP32 Health Service Delivery Models OS09 Bridging HTA for Patients with Severe Mental Illness: Regulations & Real-World A Systematic Literature Review of Practice: Lessons & Future Economic Evaluations Directions Presenter: Anne Kleijburg E3, ground level OP33 Child and Adolescent Mental OP41 Gap Analysis of EU Regulations Health Care Models: A Scoping Review Related to Real World Evidence Generation Presenter: Ingrid Zechmeister-Koss Presenter: Entela Xoxi OP34 Application of a Case-Mix Analysis in COVID-19 Management at a OP43 Translating Cell and Gene Therapy University Hospital in Malaysia HTA into Practice - Building the Plane as we Fly it Presenter: Amirah Azzeri Presenter: Paul Fennessy OS08 Empowering Healthcare Decisions: OP44 Exploring the Disconnect in Equity, Multimorbidity, Relevant Outcomes for HTA-Related RWE & AI Economic Evaluation Relative to Care Commissioning: Implications for Gilbert Suite, ground level Resource-Allocation OP37 Modelling the Effect of Multi- Presenter: Rachael Hunter indication Treatment in Multimorbid Patients Using Population-Scale Linked OP29 Impact of New Drug Indications Electronic Health Records for Healthcare After Initial Registration by ANVISA - Policy Brazil Presenter: Rhiannon Owen Presenter: Marcus Borin OP39 Real-World Evidence of Pos- OS10 Addressing Incorporation Use of Monoclonal Uncertainty in HTA & Antibodies for Psoriasis in the Brazilian Pricing Public Health System Riverbank 7, lower level Presenter: Stéfani Sousa Borges OP46 The Decision Uncertainty Toolkit: OP115 Scoping Meta-Review on Risk Measures and Visual Outputs to Methods used to Assess Artificial Support Health Technology Decision- Intelligence Based Medical Devices for making During Public Health Crises Congestive Heart Failure Presenter: Erin Kirwin Presenter: Rossella Di Bidino 84

ORALS OP47 The Risk-Based Price: Oral Session 2 Incorporating Uncertainty and Risk Tuesday 27 June, Attitudes in Health Technology Pricing 13:45 – 14:45 Presenter: Erin Kirwin OS12 RWE & Economic Evaluation in Chronic OP48 Is It Time for (Disease-Specific) Diseases Reference Models? Riverbank 6, lower level Presenter: Hossein Afzali OP51 Use of Real-World Data in Cost- OP27 Impact of Generic Entry of effectiveness Analysis of Sequential Pharmaceuticals on Drug Prices in Biologic Treatment for Rheumatoid Australia Arthritis Presenter: Hansoo Kim Presenter: Janharpreet Singh OS11 Innovations in HTA OP03 Comparative Safety and Efficacy Research & Practice of PD-(L)1 Inhibitors for Advanced Non- Squamous Non-Small Cell Lung Cancer: Riverbank 5, lower level A Bayesian Network Meta-Analysis OP171 Canadian Disease Registry Presenter: Yi Yang Inventory: Environmental Scan of the Literature OP53 Return on Investment of Fracture Liaison Services: A Systematic Review Presenter: Amanda Hodgson Presenter: Lizheng Xu OP172 International Collaboration for Translating the Peer Review of Electronic OP54 Experiences on Out-of-Hospital Search Strategies (PRESS) Checklist: A Drug Treatment for Systemic Lupus Harmonized Approach Erythematosus: A Thematic Synthesis Presenter: Amanda Hodgson Presenter: Clarice Portugal OP23 Early Detection Tools for OS13 Empowering Emotional Distress in Adult Cancer Patients in HTA: Patients in Spain: A Health Technology Opportunities and Assessment Report Challenges Presenter: María José Faraldo-Vallés Plenary Room (Hall C), ground level OP68 Exploring the Diversity of Interventions in Healthcare and Social 85 Care: A Road to Priority Setting and Sustainability Presenter: Sylvie Bouchard

ORALS OP55 Did It Matter? Developing a OP61 Value of Disinvestment: The Common Framework for Characterizing Journey from Possibility to Reality Impact of Patient Involvement in Health Technology Assessment Presenter: Izzuna Ghazali Presenter: Anke-Peggy Holtorf OP62 Development of the Oral-Health Risk Adjustment Model to Predict OP56 Conversations for Change’ – the Outpatient Dental Expenditure in Identifying Meaningful Ways to Improve Children with Autism Consumer Participation in Health Technology Assessment Processes Presenter: Mei-chi Lai Presenter: Sally Wortley OS15 HTA Innovations: Machine Learning to Real- OP58 Challenges In Maintaining Up to World Evidence Date Health Technology Assessments in Rare Diseases: Lessons from Fabry Riverbank 8, lower level Disease In Australia OP63 Incorporating Machine Learning Presenter: Michel Tchan Methods in Health-Economic Evaluations: A Case Study on Depression OP57 Consumer Engagement in Health Prevention Technology Assessment: An Australian Journey to Date Presenter: Joran Lokkerbo Presenter: Jo Watson OP106 Standing on the Shoulders of Giants: Adapting Published Health OS14 Innovative HTA: Technology Assessments on Medical Disinvestment, Digital Technologies to Singapore’s Context Health, Risk Adjustment Presenter: Lydia Ooi E3, ground level OP66 Adoption of the Who Algorithm OP59 Do Digital Health Terms Provide for Essential Medicines in the Philippine Sufficient Information to Allow for National Formulary Listing Process Health Technology Assessment? Presenter: Sheena Jasley Samonte Presenter: Rossella Di Bidino OP74 Analysis of Literature and OP60 Community Funding Prioritisation Research Foci in Overdiagnosis Based of Treatments for Rare and Ultra-Rare on CiteSpace Medical Conditions Presenter: Juntao Yan Presenter: Samson Kong 86

ORALS OS16 Advancing OP77 Distributional Cost-Effectiveness Healthcare: Repurposing, Analysis of Lung Cancer Screening Adoption & Economic for Indigenous and Non-Indigenous Analysis Populations in Australia Gilbert Suite, ground level Presenter: Jackie Roseleur OP67 Horizon Scanning for Repurposed OP78 Cost-Effectiveness of a 20-Valent Medicines Pneumococcal Conjugate Vaccine to Directly Protect Adults against Presenter: Aoife Oliver Pneumococcal Disease in England OP173 Estimating the Marginal Presenter: Diana Mendes Productivity of Health Technology Adoption OP71 Road to Public Funding of Cancer Co-dependent Technologies in Australia Presenter: Charles Yan in the Last 10-Years OP95 A Systematic Review of the Presenter: Yuan Gao Cost and Cost-effectiveness of Immunoglobulin Treatment in Patients OS19 Economic with Haematological Malignancies Evaluation & Diagnostic Technologies Presenter: Sara Carrillo De Albornoz Riverbank 3, lower level OP70 Treating Patients with Hormone- Sensitive Cancer on Endocrine Therapy OP79 Gene Expression Profiling in with Denosumab (Prolia®): A Systematic the Diagnosis of Aggressive Large B Review and Network Meta-Analysis Cell Lymphoma: An Early Exploratory Economic Evaluation Presenter: Konstance Nicolopoulos Presenter: Janet Bouttell OS18 Cost-Effectiveness of Smoking Cessation & OP80 Diagnostic Molecular Sequencing Lung Cancer Screening of DNA (Exomes and Genomes) Is Not Perfect: Implications for HTA Riverbank 4, lower level Presenter: Camille Schubert OP75 Cost-effectiveness of Brief Advice to Quit Smoking to Prevent Postsurgical OP81 Cost-Effectiveness of Human Complications in People Living with Cancer Papillomavirus Extended Genotyping for Cervical Cancer Screening in Singapore Presenter: Nikki Mccaffrey Presenter: Brandon Chua 87

ORALS OP82 Positron Emission Tomography OS21 Patient-Centered Combined with Computed Tomography Care in HTA (PET/CT) using 18F-NaF Riverbank 7, lower level Presenter: Nasrulla Shanazarov OP87 A Roadmap for Increasing the OS20 Economic Usefulness and Impact of Patient Evaluations: Diagnostic & Preference Studies in Health Technology Therapeutic Interventions Assessment (HTA) Riverbank 5, lower level Presenter: Deborah A Marshall OP83 Diagnostic Accuracy and Cost- OP88 Translating Patient Reported Effectiveness of Automated ABPI Measure Score into Specific Outcomes Measurement for Assessing Peripheral from the Patient Perspective – Example Arterial Disease in People with Leg Using Health Assessment Questionnaire- Ulceration Disability Index Presenter: Dwayne Boyers Presenter: Adrian Griffin OP84 Cost-Effectiveness of OP98 Improving Patient Involvement Testosterone Treatment (TT) for Men in Health Technology Assessments: Is it with Hypogonadism Enough to Train just the Patients? Presenter: Rodolfo Hernández Presenter: Jenniffer Prescott OP85 Cost-Effectiveness Of OP90 Multiple Myeloma: Developing a Prednisolone to Treat Bell’s Palsy in Benchmark Patient Experience Index – Children: An Economic Evaluation Australia and New Zealand Alongside a Randomized Controlled Trial Presenter: Jenni Godsell Presenter: Xiuqin Xiong OS22 Healthcare OP86 Cost-effectiveness of High- Operations & Sensitivity Troponin Testing in the Management Investigation and Management of Chest Pain in the Emergency Department E1, ground level Presenter: Aubyn Pincombe OP25 Increasing Harmonisation through Improving Uptake of Core Outcome Sets in Clinical Trials and Systematic Reviews Presenter: Sean Tunis 88

ORALS OP176 Integrating Real-World OP94 Economic Evidence on Compliance in the Assessment of Haemodialysis Access Creation Left Atrial Appendage Closure versus Procedures in Patients with End-Stage Anticoagulation Therapy in Non-Valvular Kidney Disease: A Systematic Literature Atrial Fibrillation Review Presenter: Dominic Tilden Presenter: George Papdopolous OP05 HTA Role In Carving the Pathway OS25 Advancing HTA for for Better Access to Immunotherapy in Global Health: Insights Advanced NSCLC in Malaysia and Roadmaps Presenter: Erni Zurina Romli E1, ground level OP72 Innovating to Decrease Mortality OP101 Health Technology Assessment and Resource Use in Surgical Inpatient: for Sexual Reproductive Health and ZERO project Rights Packages in Sub-Saharan Africa: Review of Evidence-Informed Presenter: Carla Fernández-Barceló Deliberative Processes Oral Session 3 Presenter: Warren Mukelabai Tuesday 27 June, Simangolwa 17:30 – 18:30 OP102 Towards Universal Health OS23 Economic Coverage: Health Technology Evaluations in Healthcare: Assessment Roadmap Development in Insights from Systematic the Emirate of Abu-Dhabi Involving the Reviews Whole Ecosystem E2, ground level Presenter: Amna Alsaeedi OP92 The Hidden Burden of Patients OP103 What to Include in a Health and Families in Rare Diseases: A Scoping Technology Assessment of Artificial Review of Economic Evaluations Intelligence-Based Technologies: Results of a Delphi Expert Survey Presenter: Deborah Marshall Presenter: Rossella Di Bidino OP93 The Cost-Effectiveness of Antiretroviral Therapy Adherence OP104 Pilot Implementation of the HTA Interventions in HIV/AIDS Patients: A Topic Prioritization in the Philippines: Systematic Review of Decision Analytic Lessons and Moving Forward Plans Models Presenter: Sheena Jasley Samonte Presenter: Ali Ahmed 89

ORALS OS26 Innovations in HTA: OP125 How can HTA Evolve to Better Processes, Perspectives Consider Benefits for Patients, their and Value Families and Carers? Riverbank 8, lower level Presenter: John Gillespie OP107 Streamlining Health Technology OP96 Adapting Patient Involvement for Assessment Process of Medical Devices Fast Track Appraisals through the Development of the Philippine Essential Medical Device List Presenter: Sam Roberts Presenter: Patrick Wincy Reyes OS29 Economic OP109 The Conceptualization and Value Evaluation in Cancer of a Disease Management Approach and Renal Disease: Cost to HTA in Canada: Findings from a Effectiveness Perspectives Qualitative Study Presenter: Marina Richardson Riverbank 4, lower level OP100 Patient Perspectives in Value OP121 Cost-Utility Analysis of a Assessment Frameworks: The Asia Supervised Exercise Intervention for Pacific Perspective Women with Early-Stage Endometrial Presenter: Alex Best Cancer OS28 Empowering Patient Presenter: Yufan Wang Involvement in HTA: Collaborative Approaches OP122 Economic Evidence to Support & Future Perspectives Expanding Use of Existing Positron- Emission Tomography Technology as Plenary Room (Hall C) ground Diagnostic Tool for High-Risk Cancer level Patients OP116 Building Alignment Between Presenter: Michelle Tew Industry, Academia and Patients on HTA Methods OP123 Lifetime Cost-Effectiveness Presenter: Colman Taylor Analysis in Patients with Early Hepatocellular Carcinoma Receiving 90 Two Competitive Treatments: Liver Transplantation versus Hepatic Resection. Presenter: Yih-Jyh Lin OP124 Cost-Effectiveness of End Stage Renal Disease Treatment Methods in Türkiye Presenter: Mustafa Kılıç

ORALS OS30 Evaluating OS31 Advancements Effectiveness and in HTA and Healthcare Cost-Effectiveness in Outcomes Healthcare Interventions Riverbank 3, lower level E3, ground level OP133 COVIDIAGNOSTIX: HTA OP126 Clinical and Economic Evaluation for COVID-19 Serological Tests as of the Effectiveness of the Cerebrolysin Companion Diagnostics to Employ the in Neurological Patients with Post-Stroke Vaccination Complications in Kazakhstan Presenter: Giuseppe Banfi Presenter: Andrey Avdeyev OP134 Mapping the Health of the Nation OP127 The Cost-Effectiveness of the Outcomes Scale to the EQ-5D using Anti-VEGF Treatments for Age-Related the Pharmacotherapy Monitoring and Macular Degeneration in the Italian Outcome Survey Healthcare Setting Presenter: Anne Kleijburg Presenter: Michele Basile OP135 Machine Learning and Cancer OP128 Uncertainties in the Cost- Registry: Evaluation of the Effectiveness Effectiveness Analysis of the of Case Coding. Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Presenter: Rosalia Ragusa Presenter: Stefani Borges OP119 Collectively Improving the Quality Use of Highly Specialised OP129 A Cost-Utility Analysis of Medicines: Starting with Biologics Denosumab (Prolia®) for Treating Osteoporosis in Postmenopausal Presenter: Jonathan Dartnell Women: A Swiss Healthcare Payer Perspective OS32 Global HTA: Challenges and Presenter: Danielle Stringer Opportunities Riverbank 7, lower level OP136 A Comparison of HTA Recommendations in Australia, Canada and England: Is There Opportunity for Further Alignment? Presenter: Tina Wang 91

ORALS OP137 A Qualitative Exploration of the Oral Session 4 National Institute for Health and Care Wednesday 27 June, Excellence’s Impact on International 10:35 – 11:20 Health Technology Assessment OS34 Innovations in HTA: Presenter: Martina Garau Expert Elicitation, Disease Progression Analysis & OP138 Navigating High-Cost Medicines: Diagnostic Pathways Promoting Consistent, Evidence-Based Use of High-Cost Medicines in a Fiscally E2, ground level and Equitable Responsible Manner OP141 Expert Knowledge Elicitation in Presenter: Naomi Burgess Health Technology Assessment: Our Experience Using the Sheffield Elicitation OP140 An Initiative to Identify the Long- Framework Term Effects of COVID-19: Ministry of Health (MoH) COVID-19 Follow-Up Presenter: Danielle Stringer Centers OP142 Progression Analysis vs Presenter: Olgun Şener Traditional Methods to Quantify Slowing of Disease Progression in Alzheimer’s OS33 HTA & Economic Disease Evaluations Presenter: Milana Ivkovic Riverbank 6, lower level OP168 Costs and Effectiveness of Whole OP112 Evaluation of a Self-Administered Exome Sequencing (WES) in Patients Smart Phone-Based Application as a with Unsolved Rare Disease through the Wellness Measure in a Clinical Trial of Diagnostic Pathway Zanubrutinib Presenter: Deborah A Marshall Presenter: Keri Yang OS35 Health Initiatives: OP38 Evaluation of High-Cost Medicine Knowledge, Screening, for a Rare Disease: 16-Year Cohort of and Economic Impact Imiglucerase Use for Gaucher Disease in Brazil E3, ground level Presenter: Marcus Borin OP144 Impact of a Training Program for General Population on the Knowledge of OP65 Addressing System Need Through Aortic Valve Stenosis Piloting Early Value Assessment of Digital Therapies for Mental Health Presenter: Carla Fernández-Barceló Presenter: Jenniffer Prescott 92

ORALS OP130 Estimating Economic Burden OP150 An Inventory of Policy Levers for of “Human Immunodeficiency Virus / Influencing Appropriate Care Acquired Immunodeficiency Syndrome” in Turkiye towards Next Decade Presenter: Ken Bond Presenter: Birol Tibet OP151 Health Technology Assessment in Switzerland - Current and Future OS36 Impact of HTA: Challenges Insights from Healthcare Systems, Hospitals, and Presenter: Nicolas von Dombrowski Stakeholders OP114 Health Technology Assessment Plenary Room (Hall C), ground of Digital Technologies: Results from level Two Past Examples and Thoughts for the Future OP147 Measuring HTA Impact on Introduction of Transcatheter Aortic Presenter: Jamie Erskine Valve Replacement in A Private Healthcare System OS38 Advancing HTA: Bridging Data Access & Presenter: Marcus Borin Proportional Approaches and Patient Outcomes OP148 Influence of the Hospital-Based HTA Unit on the New Technologies Riverbank 7, lower level Transfer at the National level in Kazakhstan OP153 Access to Real-World Data for the Use in Health Technology Presenter: Andrey Avdeyev Assessment – Still Work to be Done. OP149 How to Improve the Impact Presenter: Hansoo Kim of Health Technology Assessment: A Stakeholders’ Perspective in Spain OP154 Horses For Courses: Developing A Proportionate Approach to Health Presenter: María José Faraldo-Vallés Technology Assessment in England OS37 Future of HTA: Presenter: Jenniffer Prescott Policy, Challenges & Digital Innovation OP143 Association of Different Venous Access Device and Health-Related Riverbank 8, lower level Quality of Life among Patients with Breast Cancer in China Presenter: Liu Liu 93

ORALS OS39 Assessing Medical OP174 HTA and Economic Evaluations Interventions for a Genomic Strategy in Italy Riverbank 3, lower level Presenter: Eugenio Di Brino OP156 Systematic Review and Meta- OS42 Analyzing HTA in Analysis of the Perioperative Association Brazil: Decision Criteria, of Gabapentinoids with Sedation and RWE & Medication Respiratory Depression after Abdominal Exclusion Surgery Riverbank 4, lower level Presenter: Laure Taher Mansour OP165 Changing Decision Criteria: OP157 Evaluating the Clinical and An Analysis of Health Technology Economic Impact of Adopting a Closed Assessment Reports to Brazilian Health Peripheral Intravenous Catheter System Unified System in a Japanese Hospital Presenter: Stefani Borges Presenter: Yan Ma OP152 Use of Real-World Evidence by OP158 Point of Care Testing in Primary the Brazilian HTA Committee (CONITEC) Care: How to Add Value to Economic for Monitoring of Health Technologies Evidence to Argue for Adoption Presenter: Clarice Moreira Portugal Presenter: Rachael Hunter OP167 An Analysis of Medication OS41 Local Economic Exclusion Reports in the Health Evaluation and HTA Technology Assessment Process for the Brazilian Unified Health System Riverbank 6, lower level Presenter: Stefani Borges OP162 Making Local Economic Evaluation More Relevant: Using Expert Elicitation to Adjust Published Intervention Effects to Reflect Local Context Presenter: Jodi Gray OP163 Applying a Local Economic Evaluation Framework to Make Evaluations More Relevant for Local Decision Makers Presenter: Jodi Gray 94

HTAi 2023 Annual Meeting Tuesday, June 27th, 09:25 – 10:40 ACST Plenary Room, Adelaide Convention Cntr. From Data to Health: Enhanced Evidence Methods and Practical Applications for HTA and Treatment Access in Prostate Cancer Join our expert faculty to hear about methodological innovations supporting access and clinical decision-making in the fast-evolving prostate cancer treatment landscape LIVING NETWORK META-ANALYSIS Indirect comparative evidence for clinically relevant treatment decision-making PREFERENCE METHODOLOGY Physician and patient preferences with regional-specific applicability DISTRIBUTIONAL COST- EFFECTIVENESS ANALYSIS Incorporating health equity considerations in treatment value quantification Bayer Healthcare Pharmaceuticals, Inc. 100 Bayer Boulevard, Whippany, NJ 07981, USA MAC-PF-ONC-AU-0004-1 06/2023 95

A Turning Point for HTA? Meta Networks and Innovation June 15-19, 2024 htai.org #HTAi2024Seville 96

Posters

POSTERS Poster Presentations AD G V B F W HJ K X Y Z MO R T L NP QS U 98

POSTERS Poster Presentations Session 1: PP110 Knowledge Transfer from Scoping Monday June 26, Review into Primary Research in Che 10:20 – 10:35 Context of Clinical Practice Guidelines Update Revolutionizing Healthcare: Digital Innovations and Presenter: Trinidad Sabalete Complex Decision-Making Empowering Patient-Centered Poster Stand A, Halls F & G Care: From Training and Capacity Building to Global PP53 Increasing Emergence of Novel Perspectives and Best Practices Digital Health Technologies Identified Through Horizon Scanning Poster Stand M, Halls F & G Presenter: Zhen Long Ng PP11 Patient Involvement in Drug Evaluations to Inform Funding Decisions: PP55 Citizens’ General Needs A Singapore Case Study Assessment In SOTERIA Project: ‘User- friendly Digital Secured Personal Data Presenter: Ping-Tee Tan And Privacy Platform’ PP13 Results of an International Survey Presenter: Eunate Arana-arri About Barriers in Patient Involvement in Health Technology Assessment of Digital PP76 From Hospital-based HTA to Health Technologies. Treatment Decision: What Decisions Actually Result After HTA in a Resource Presenter: Edurne Gallastegui-Calvache Constrained Environment? PP38 Designing a Training and Capacity Presenter: Anita Fitzgerald Building Pathway in Patient Involvement Advancing Health Outcomes: Presenter: María José Faraldo-Vallés Exploring the Cost- Effectiveness and Safety of PP133 What Services and Products Innovative Strategies and Should an HTA Agency Provide? Interventions Presenter: Beatriz Casal-Accion Poster Stand U, Halls F & G PP36 Immersion in Water During PP105 Efficacy, Effectiveness and Childbirth. Safety of Letermovir for Prophylaxis of cytomegalovirus Infection and Disease Presenter: Iñaki Gutierrez-Ibarluzea Post-Allogeneic Hematopoietic Stem Cell Transplantation PP37 Immersion in Water During Childbirth: A Survey to the Spanish Presenter: Juliana Alvares-Teodoro National Health System Presenter: Iñaki Gutierrez-Ibarluzea 99

POSTERS Driving Healthcare Access PP48 Cardiac Implantable Electronic and Outcomes: Strategies Device (CIED) Infections in New South for Achieving Universal Wales, Australia: A Non-Interventional Coverage and Optimizing Value Study Utilising Linked Secondary Data. Assessment Presenter: Michelle Hill Poster Stand P, Halls F & G PP49 Cost of Cardiac Implantable PP18 Unlocking The Potential of Medical Electronic Device (CIED) Infections in Device Reimbursement in India for Australia: A Private and Public Sector Better Health Outcomes Payer Perspective Presenter: Arif Fahim Presenter: Michelle Hill PP44 Time is Now: Advancing Value PP50 Early Diagnosis Effect of Newborns Assessment of Cancer Therapies to Help with Critical Congenital Heart Disease Eliminate Cancer as the Cause of Death Using National Health Insurance Data in South Korea Presenter: James Ryan Presenter: Miyoung Choi PP67 What Patients Want – Optimising Oncology Value Assessment to The Poster Presentations Session 2: Goals of Patients Tuesday, June 27, 10:45 – 11:00 Presenter: Richard Vine Advancing Health Technology PP118 The Value of New Antibiotic Assessment: From Streamlined Treatment Strategies in Zhejiang Frameworks to Global Province, China Collaboration and Regulatory Challenges Presenter: Yang Wenqianzi Poster Stand B, Halls F & G Advances in Cardiovascular Health: Insights from Real- PP4 Developing a Streamlined Health World Data, Infection Control, Technology Assessment Framework and Early Diagnosis Strategies for Positron Emission Tomography/ Computed Tomography for Uncommon Poster Stand S, Halls F & G Cancers PP47 Experience and Its Implication Presenter: Ning Ma for Reassessment of the Transcatheter Aortic Valve Implantation Using Real World Data Presenter: Jung Mi Park 100